



Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B

Itziar Oyagüez,* María Buti,** Max Brosa,*** Magdalena Rueda,**** Miguel A. Casado*

*Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain. **Hospital Vall d'Hebron, Barcelona, Spain.
Oblikue Consulting, Barcelona, Spain. *Gilead Sciences, Madrid, Spain.

ABSTRACT

Introduction. Chronic hepatitis B (CHB) is associated with high burden and healthcare costs. Virologic response achieved with antivirals is associated with progression avoidance. This study aimed to estimate the efficiency and clinical impact of antiviral strategies in CHB patients. **Material and methods.** A Markov model estimated lifetime complications and direct costs in both, HBeAg-positive and HBeAg-negative cohorts. Strategy 1 (71% of treated population) and strategy 2 (100%), both based on pegylated interferon (peg-IFN) followed by oral tenofovir or entecavir, were compared to no treatment. Progression was based on HBV-DNA levels. Rescue therapy with oral antivirals was applied for peg-IFN failure. Disease costs (€, 2014) and utilities were obtained from literature. **Results.** Compared to natural history, strategy 1 increased QALY (3.98 in HBeAg-positive, 2.16 in -negative cohort). With strategy 2, survival was up to 5.60 (HBeAg-positive) and 3.05 QALY (in HBeAg-negative). The model predicted avoidance of 128 and 86 carcinomas in HBeAg-positive and -negative patients with strategy 1, and up to 181 and 121 in HBeAg-positive and -negative for strategy 2. Total cost increased up to €102,841 (strategy 1) and €105,408 (strategy 2) in HBeAg-positive, and €85,858 and €93,754 in HBeAg-negative. A €1,581/QALY gained ratio was estimated versus the natural history for both strategies. In conclusion, increasing antiviral coverage would be efficient, reducing complications.

Key words. Chronic hepatitis B. Clinical impact. Efficiency. Oral antivirals. Peginterferon.

INTRODUCTION

Hepatitis B infection is a global public health problem.¹ Around 2 billion people have been exposed worldwide, and near 350 million have developed a chronic hepatitis B (CHB).² Hepatitis B virus (HBV) is responsible for 600,000 annual deaths each year.³

Preventive measures by means of widespread use of vaccine, have been associated to decrease the prevalence of CHB in some regions, although absolute number of HBsAg positive persons has increased from 223 million in 1990 to 240 million in 2005.⁴

The hepatitis B burden is particularly heavy in endemic countries, where liver cirrhosis and hepatocellular carcinoma (HCC) are leading causes of death, but even in developed countries with universal vaccination programs and availability of efficacious treatment, HBV-related dis-

eases represent an enormous economic and social burden.⁵

HBV replication measured by serum HBV DNA levels, has been identified as an independent predictor of disease progression. Therefore sustained suppression of viral replication is essential to prevent fibrosis progression. The European Association for the Study of the Liver (EASL) 2012 guidelines suggest that therapy must reduce HBV DNA to as low a level as possible, ideally below the lower limit of detection by the real-time PCR assay.⁶

The ultimate goal of CHB treatment is to increase survival by preventing the development of cirrhosis, liver failure, and HCC. Three drugs have been recommended as a first-line therapy for patients with CHB, entecavir, tenofovir and pegylated-interferon (peg-IFN) given as a monotherapy. These recommendations were based on efficacy results and no or minimal risk of HBV drug resistance

observed in clinical trials.⁷ In addition, nucleos(t)ide analogues have shown similar results in real-life studies while interferon has an immune modulator effect with less potent antiviral action.⁶

The present analysis aimed to estimate the influence of two treatment strategies in the clinical burden of CHB patients, by assessing their effects on disease progression and survival. In addition, the efficiency of the antiviral strategies was assessed, by means of a cost-effectiveness analysis.

MATERIAL AND METHODS

A previously developed Markov model,⁸ simulating long-term clinical outcomes in CHB patients was used to estimate the survival and the lifetime costs in Euros of a cohort of 1,000 patients with CHB. This cohort which reflected the patients enrolled in the studies GS102 and 103, was adapted to the proportion of HBeAg positive patients identify in the majority of the European countries.⁹ The study was performed under the perspective of Spanish National Health System.

Interventional therapeutic strategies

Two different strategies of antiviral treatment were explored following the current EASL recommendations for CHB management.⁶

The first strategy (strategy 1) considered treatment for 71% of patients diagnosed with CHB and candidates to therapy based on the estimation of a survey of CHB patients management practices in the European Union.¹⁰ The second strategy (strategy 2) increased the rate of treatment assuming a full treatment coverage (100% of treated patients).

The assessed drugs were those recommended as a first line therapy, peg-IFN alpha-2a (peg-IFN; 180 μ g weekly for 48 weeks of treatment) and indefinite oral antiviral with either entecavir (0.5 mg daily) or tenofovir (300 mg daily) at different proportions for each defined cohort trying to simulate the current clinical practice. Oral antivirals (tenofovir-50% and entecavir-50%) was considered in 85% of patients already treated in each scenario for HBeAg-positive cohort, and in 95% of treated patients for HBeAg-negative population. Therefore peg-IFN represented 15% of therapies in HBeAg-positive treated patients, and 5% in HBeAg-negative population.

Analyses were separately performed for both, HBeAg-positive and HBeAg-negative cohorts.⁹

Transition probabilities

The health states included in the model (CHB, compensated cirrhosis, decompensated liver disease, HCC, transplant and death) were the commonly used to reflect the progression of disease's natural history.^{8,11}

One-year probabilities applied to simulate the evolution through these states were based on the virological response, depending on HBV DNA levels.¹¹ Studies have shown that persistent reduction of serum HBV DNA below the lower limit of detection by real-time PCR assays is associated to biochemical remission, histological improvement and prevention of disease-related complications.¹²

For this reason, the original model⁸ was modified, including the potential regression of cirrhosis as have shown in long term studies with tenofovir (74%, at 5-years)¹³ and entecavir¹⁴ (Figure 1).




Figure 1. Markov diagram.

Failure, resistance and rescue therapies

Patients initially treated with peg-IFN who did not achieve immune control (HBV DNA < 2,000 IU/mL and normal ALT levels) after 48 weeks of treatment were re-treated with oral antivirals (50% entecavir and 50% tenofovir). According to the literature, a first year antiHBe seroconversion of 32% was considered in HBeAg-positive patients treated with 48 weeks of peg-IFN.⁶ This seroconversion was maintained overtime in the 81% of cases¹⁵ given a lifetime adjusted seroconversion equal to 25.9%. In HBeAg-negative patients, 19% of them achieved serum HBV DNA levels < 60-80 IU/mL after 48 weeks of therapy,⁶ being a failure rate of 81%.

The antiHBe seroconversion rates^{6,16} in HBeAg-positive patients treated with tenofovir were 21% at year 1 of therapy,⁹ 26% at year 3,¹⁷ and up to a maximum rate of 40% at year 7.¹⁸ The same rates were applied for entecavir in absence of long-term data in clinical trials (only results for 3 years of follow-up were identified). As recommended by guidelines, oral therapy was stopped 12 months after anti-HBe seroconversion.⁶ The rate of HBsAg loss considered in HBeAg-positive cohort was 12%.¹⁸ No HBsAg loss was applied to HBeAg-negative patients. No resistance to tenofovir was considered based on the results published.¹⁹ A resistance rate of 1.2% at 5 years²⁰ was considered for entecavir. Patients with HBV resistant to entecavir were rescued by adding on tenofovir.

Treatment discontinuations

Treatment discontinuations for efficacy of oral antivirals were allowed for those HBeAg-positive patients achieving HBeAg loss and seroconversion to anti-HBe and also for HBeAg positive or negative who presented HBsAg loss.

No more discontinuations were applied further the 7 years mentioned period. After discontinuation, the patient's progression was equivalent to the natural disease.

Analysis

Expected outcomes were calculated in terms of survival, as well as the accumulated number of HCC cases at each patient cohort.

The cost-effectiveness results were expressed as incremental cost in euros, per survival increase measured as life year gained (LYG) and quality adjusted life years (QALY) gained.

QALY were derived from LYG, applying different utility figures, obtained for each model health state.⁸

The model established the incremental cost-effectiveness ratio (ICER) for each one of the defined-antiviral strategies compared to the reference case (natural disease history). Additionally the ICER of strategy 2 compared to strategy 1 was calculated, to assess the influence to increase the treatment coverage from 71% to 100% of population.

Beyond the first year, an annual discount rate of 3% was applied to costs and health benefits to allow for time preference into current values.²¹

Costs

Only direct health care costs related to pharmaceutical and disease management costs⁸ were included in the analysis.

Drugs ex-factory prices for pharmaceutical costs calculation were taken from a national database,²² applying the 7.5% mandatory deduction.²³ Pharmaceutical costs calculations did not consider potential discontinuations due to adverse events.

Costs were expressed in euros (€, year 2014 values). Unitary costs were updated and inflated to 2014, when applicable, with Consumer Prices Index (Table 1).

Table 1. Unitary costs (€, 2014). Pharmaceutical and disease management costs.

	Brand name	Exfactory price	Exfactory-7.5%
Pharmaceutical costs²²			
Tenofovir	Viread® (245 mg, 30 tablets)	€288.70	€8.9
Entecavir	Baraclude® (0.5 mg, 30 tablets)	€390.00	€12.0
Pegylated-interferon alpha-2a	Pegasys® (180 mcg, 4 syringes, 0.5 mL)	€765.71	€25.3
		First year	Subsequents years
Disease management costs⁸			
Chronic Hepatitis B	€1,413.52	€1,287.57	
Compensated cirrhosis	€1,681.67	€1,395.00	
Decompensated cirrhosis	€3,354.71	€1,681.67	
Hepatocellular carcinoma	€7,201.58	€7,529.57	
Liver trasplantation	€147,939.81	€46,261.82	
Death	€7,521.99	-	

Sensitivity analysis

Sensitivity analysis was performed to test the model's robustness. Two alternative scenarios were defined: a fast and slow disease progression scenario. In the fast progression scenario, the base case transition probabilities were increased +10%, together with reduction of -10% of the cirrhosis regression rate. In the slow progression, transition probabilities decreased 10%, while cirrhosis regression rate increased its value +10%.

Probabilistic sensitivity analysis (PSA) was also performed through 1,000 iterations of a second order Monte-Carlo simulation. Beta distribution was applied to transition probabilities, and lognormal distribution was used for disease management costs, assuming a standard deviation of 10% from mean values. Results were plotted in a cost-effectiveness plane, and acceptability curves were constructed.

RESULTS

The results of the model showed that both treatment strategies resulted more effective than no thera-

py for both HBeAg-positive and HBeAg-negative populations.

Strategy 1 (treating 71% of population) increased patient survival, yielding 3.50 LYG and 3.98 additional QALY in HBeAg-positive cohort and 1.51 LYG and 2.16 additional QALY in HBeAg-negative cohort, compared to natural history. Strategy 2 (full treatment coverage) increased survival up to 4.93 LYG and 5.60 additional QALY and 2.13 LYG and 3.05 QALY gained for HBeAg-positive and -negative populations, respectively.

The avoided number of HCC cases also measured health benefits of antiviral therapies. For the study horizon, the model predicted 361 and 276 HCC episodes per 1,000 patients in HBeAg-positive and -negative populations. The strategy 1 (71% of treatment coverage) reduced the number of HCC to 233 and 190 cases per 1,000 patients for HBeAg-positive, and HBeAg-negative populations, respectively (Table 2).

The overall estimated total costs for untreated were €96,555 in HBeAg-positive and €66,527 in HBeAg-negative cohort.

Total cost increased up to €102,841 and €105,408 for strategy 1 (71% of treatment coverage) and strategy 2 (100%

Table 2. Accumulated number of HCC per 1,000 patients over time.

Strategies	5 years	10 years	15 years	20 years	30 years	40 years
HBeAg-positive						
Natural history	87	159	216	261	324	361
Strategy 1	53	92	125	153	199	233
Strategy 2	39	65	88	109	148	180
HBeAg-negative						
Natural history	74	134	181	215	257	276
Strategy 1	44	79	107	131	168	190
Strategy 2	32	56	77	97	132	155

Strategy 1: 71% treated patients. Strategy 2: 100% treated patients.

Table 3. Base case cost-effectiveness results.


Strategies	Total cost	LYG	QALY	ICER (€/LYG) strategy vs. natural history	ICER (€/QALY gained) strategy vs. natural history
HBeAg-positive					
Natural history	€96,555	15.18	12.00		
Strategy 1	€102,841	18.68	15.98	€1,794	€1,581
Strategy 2	€105,408	20.11	17.60		
HBeAg-negative					
Natural history	€101,249	14.26	10.89		
Strategy 1	€121,601	17.70	15.02	€5,913	€4,923
Strategy 2	€129,914	19.11	16.71		

Strategy 1: 71% treated patients. Strategy 2: 100% treated patients. LYG: life year gained. QALY: quality adjusted life year. ICER: incremental cost-effectiveness ratio.

Table 4. Sensitivity analyses results. Alternative scenarios with fast and slow disease progression.

	Fast progression +10% for transition probabilities, -10% cirrhosis regression rate			Slow progression -10% for transition probabilities, +10% cirrhosis regression rate		
	Total cost	QALY	ICER (€/QALY gained) strategy vs. natural history	Total Cost	QALY	ICER (€/QALY gained) strategy vs. natural history
HBeAg-positive						
Natural history	€94,592	11.47		€97,788	12.56	
Strategy 1	€101,798	15.56	€1,761	€103,471	16.39	€1,484
Strategy 2	€104,742	17.24	€1,761	€105,793	17.96	€1,484
HBeAg-negative						
Natural history	€99,449	10.36		€102,209	11.45	
Strategy 1	€120,198	14.75	€8,104	€122,633	15.30	€5,302
Strategy 2	€128,672	16.54	€8,104	€130,975	16.87	€5,302

Strategy 1: 71% treated patients. Strategy 2: 100% treated patients. LYG: life year gained. QALY: quality adjusted life year. ICER: incremental cost-effectiveness ratio.

**Figure 2.** Acceptability curves of treatment strategies vs. natural history.

of treatment coverage) in HBeAg-positive population. The estimated ICER was €1,581 per QALY gained vs. the natural history for both scenarios.

In HBeAg-negative population, total costs accounted €85,858 for strategy 1 with 71% of treatment coverage and €93,754 for strategy 2 with 100% of treatment coverage. The ICER resulted €8,942 per QALY gained with any of the treatment strategies assessed compared to the natural history used as reference.

The treatment strategies assessed yielded ICER below the threshold used in most (66%)²⁴ of the economic evaluations performed for Spanish setting (€30,000/QALY), therefore could be considered as cost-effective alternatives compared to no treatment. Detailed values are shown in table 3.

The estimated ICER decreased, in both HBeAg-positive and -negative cohorts, in the slow disease progression

scenario tested, and increased in the fast disease progression analysis up to €1,761 per QALY gained and €8,104 per QALY gained in HBeAg-positive and -negative cohorts, respectively (Table 4).

In PSA including 1,000 Monte Carlo iterations, all the treatment strategies resulted cost-effective compared to reference case in 99.6% and 99.9% of simulations for any threshold higher than €15,000/QALY in HBeAg-positive and -negative cohorts, respectively (Figure 2).

DISCUSSION

The present findings show that with the current treatment rate in clinical practice there a reduction in the number of HCC and an increase in survival. However, higher treatment coverages on populations were associated to bet-

ter effectiveness estimates in both HBeAg-positive and -negative populations. Higher benefits in terms of preventing HCC cases were also observed, approximately 180 HCC cases per 1,000 inhabitants could be prevented in HBeAg-positive cohort with a full treatment coverage and up to 121 HCC cases per 1,000 inhabitants in HBeAg-negative cohort.

Efficiency of antiviral strategies compared to the scenario of the disease natural history without treatment was demonstrated and are consistent with those reported by other authors which explored the cost-effectiveness of antiviral strategies in HBeAg-positive and HBeAg-negative cohorts in European population.²⁵ The increase of the treatment coverage from 71% up to 100% was associated to better effectiveness estimates (higher survival and less HCC cases over time) at the same cost-effectiveness ratio, for both patients cohorts, HBeAg-positive and -negative.

Apart from the inherent limitations to any modelling study, some of them directly related to heterogenous profile of the CHB, that avoid capturing the full dynamic aspect of the disease, even in a rigorously performed mathematical model, the following limitations are worth mentioning:

The cost of different CHB stages was obtained from published sources⁸ and could slightly differ from the present patient management, which could include novel treatments as sorafenib and new diagnostic techniques as FibroScan. However, no large variations are expected to occur over results if these values are modified.

In contrast with European guidelines,¹⁶ the current Spanish recommendations³⁰ do not consider peg-IFN therapy for HBeAg-negative patients. In the present analysis a 3.5% was applied in order to capture the most reliable scenario across Europe.

One of the main novelties of the present model is that in contrast to the original one,⁸ it included regression of cirrhosis cases based on the available evidence that have demonstrated its occurrence in patients achieving sustained virological response after long-term oral antiviral therapy.

The rates applied in the model (74% of cirrhosis regression at 5 years) corresponded to tenofovir,¹³ because, although a similar phenomenon seems to happen also following entecavir treatment,¹⁴ the reduced sample of cirrhotic patients in the studies avoided calculation of a regression rate.

Derived from published series, the HCC accumulated ratios at approximately 5-years of follow-up period, could be established from 6% to 19% for not treated populations, 2%²⁶ to 16%²⁷ in interferon treated patients, and 0.7%²⁸ to 6.6%²⁹ for oral antiviral therapies.

The design of the current model does not allow the distinction between pegylated interferon and oral anti-

ral, but the projected HCC incidences do not differ much more from the values here above mentioned, and are among the wide intervals showed. The estimated accumulated incidence of HCC at 5-years resulted around 7.6% in HBeAg-positive and 38% in HBeAg-negative populations for no treated patients. Incidences as low as 0.1% and 0% (for HBeAg-positive and HBeAg-negative cohorts, respectively) were observed following any treatment strategy. In line with conclusions from a recent review of the long-term efficacy of antiviral treatment in the prevention of HBV-related HCC³⁰ the results from the present model confirmed the protective effect in lowering the risk of HCC development with the assessed treatment strategies.

Durable HBeAg seroconversion is an important therapeutic endpoint, associated to better outcomes.³¹ This effect was included in the the model, allowing patients to discontinue the treatment. Additionally to the associated reduction in total cost due to the lower drugs consumption over long time, there are other benefits difficult to quantify, in terms of patient quality of life that should be kept in mind.

The results from the sensitivity analyses confirmed robustness of the assumptions and the model.

The external validity of the results, in terms of transferability to other settings, particularly to routine clinical practice derives directly from the potential differences in patient management. These outcomes apply to Spain, should be precautionary interpreted in regard to a potential extrapolation to a different setting.

Cost-effectiveness of CHB antiviral therapies have been examined by different studies. Comparisons of cost estimates obtained from these studies are often difficult, due to differences on methodology (comparators, time horizon, perspective, year of analysis) and heterogeneity of populations. However, entecavir and tenofovir seem to be cost-effective interventions for the treatment of patients with CHB in many health systems.³²

The current analyses aimed to estimate preventable burden of CHB, by means of establishment of available antiviral therapies. Any effort conducted to increase the treatment antiviral coverage in CHB populations, both HBeAg-positive and -negative would be accompanied by the long-term reduction of the CHB complications, as HCC cases mainly.

In conclusion, antiviral therapy must be a generalized option in CHB infected patients. Based on the present results any campaign designed to increase the coverage of treatment in CHB patients, would be efficient and should be encouraged in order to improve health benefits in infected patients, in terms of survival, and by reduction of HCC cases.

ABBREVIATIONS

- **CHB:** Chronic Hepatitis B.
- **EASL:** European Association for the Study of the Liver.
- **HBV:** Hepatitis B virus.
- **HCC:** Hepatocellular carcinoma.
- **ICER:** Incremental cost-effectiveness ratio.
- **LYG:** Life year gained.
- **Peg-IFN:** Pegylated interferon.
- **PSA:** Probabilistic sensitivity analysis.
- **QALY:** Quality adjusted life year.

CONFLICT OF INTEREST AND FINANCIAL SUPPORT

The present work was done through an unrestricted grant received from Gilead, for input collection, model customization, data interpretation and medical writing.

MBrosa is an employee of Oblikue, a consultant company, responsible for modelling and analysis. IO and MAC are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultant company who received a grant for collecting data, reviewing the model's assumptions and drafting the manuscript. MR is an employee of Gilead Sciences. MButi declares have not any conflict of interest.

AUTHORS CONTRIBUTION

MBrosa, MButi, MR and MAC conceived the project. MBrosa developed the original model and performed the customization. IO and MAC, collected the inputs and drafted the manuscript. MButi and MR validated the inputs. All authors contributed to the data analysis and interpretation of the findings.

All authors have read and approved the final version of the manuscript.

ACKNOWLEDGEMENTS

Authors thank Virginia Lozano former employee by PORIB who provided support on input collection, and Teresa Caloto, former employee by Gilead Science who provided support on model's assumption validation and results interpretation.

REFERENCES

1. Ma H, Jia J. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue. *Liver Int* 2013; 33(Suppl. 1): 133-6.
2. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. *Gastroenterology* 2012; 142: 1360-8.
3. World Health Organization. Hepatitis B vaccines. *Wkly Epidemiol Rec* 2009; 84: 405-20.
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012; 30: 2212-9.
5. García-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. *J Viral Hepat* 2011; 18: e453-60.
6. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; 57: 167-85.
7. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006; 354: 1011-20.
8. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. *J Hepatol* 2009; 51: 640-6.
9. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 2008; 359: 2442-55.
10. Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. *J Viral Hepat* 2010; 17: 624-30.
11. Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. *Eur J Gastroenterol Hepatol* 2008; 20: 320-6.
12. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. *Hepatology* 2003; 37: 1309-19.
13. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; 381: 468-75.
14. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010; 52: 886-93.
15. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology* 2008; 135: 459-67.
16. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. *J Viral Hepat* 2010; 17: 16-22.
17. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, et al. Three-Year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. *Gastroenterology* 2011; 140: 132-43.
18. Marcellin P, Gane EJ, Tsai N, Flisiak R, Petersen J, Gurel S, Kotzev IA, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. *Hepatology* 2013; 58: 649A.

19. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawwalder J, Kitrinos K, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. *Hepatology* 2011; 53: 763-73.
20. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 2009; 49: 1503-14.
21. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J. Spanish recommendations on economic evaluation of health technologies. *Eur J Health Econ* 2010; 11: 513-20.
22. General Council of Pharmacists Official College. Botplus web 2.0. Available at URL: www.portalfarma.com (Accessed on June 2014).
23. Royal Decree-law. Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. BOE de 24 de Mayo 2010:126. Available at: www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf (Accessed on June 2014).
24. Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. *Eur J Health Econ* 2012; 13: 723-40.
25. Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, et al. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. *Value Health* 2015; 18: 800-9.
26. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. *J Hepatol* 2007; 46: 45-52.
27. International Interferon-alpha Hepatocellular carcinoma study group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. *Lancet* 1998; 351: 1535-9. Erratum in: *Lancet* 1998; 352: 1230.
28. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. *Antivir Ther* 2007; 12: 1295-303.
29. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. *J Hepatol* 2010; 53: 118-25.
30. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. *Hepatology* 2013; 57: 399-408.
31. Buti M, García-Samaniego J, Prieto M, Rodríguez M, Sánchez-Tapias JM, Suárez E, Esteban R. Consensus document of the spanish association for the study of the liver on the treatment of Hepatitis B infection (2012). *Gastroenterol Hepatol* 2012; 35: 512-28.
32. Buti M, Oyagüez I, Lozano V, Casado MA. Cost-effectiveness of first-line oral antiviral therapies for chronic hepatitis B: A systematic review. *Pharmacoeconomics* 2013; 31: 63-75.

Correspondence and reprint request:

Itziar Oyagüez, BSc, MSc.

Pharmacoeconomics & Outcomes Research Iberia.

Pº Joaquín Rodrigo 4-I. Pozuelo de Alarcón, 28224, Spain.

Tel.: + 34 91-715-9147. Fax number: + 34 91-715-9469

E-mail: ioyaguez@porib.com